Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Accelerate Elimination of Drug-Lag: PS Okamoto
January 17, 2011
- JPA Opposed to Unification of Basic Dispensing Fees
January 17, 2011
- Korosho Considering PAL Amendment in 2012: Mr Masugi
January 17, 2011
- Korosho to Enhance Measures against ifestyle Diseases, Cancer, New-Types of Influenza
January 17, 2011
- Premium for New Drug Development Effective for Solving Drug-Lag Problem: MED Director
January 17, 2011
- Safety Measures for Incretin-Related Drugs Insufficient: Medwatcher Japan
January 17, 2011
- HSB's Cancer-Related Budget Up ¥2.7 Bil. to ¥34.3 Bil. in FY2011
January 17, 2011
- Korosho Requires Thorough Explanations on OTC Cold Medicines before Sale
January 17, 2011
- Korosho to Require More Data Electronically on Clinical Trials
January 17, 2011
- WAKAMOTO Launches Vitreous Surgery Adjuvant MaQaid
January 17, 2011
- Tasigna Approved in 1st-Line Therapy for CML: Novartis
January 17, 2011
- Perpetuation of New Premium Top-Priority Issue in 2011: FPMAJ President Shoda
January 17, 2011
- FDA Grants Supplemental Approval for Roche's Actemra
January 17, 2011
- Bayer, J&J Apply for Rivaroxaban for SPAF in the US, Europe
January 17, 2011
- MINCLEA for Inhibiting GI Peristalsis: ASKA, Nihon Pharm.
January 17, 2011
- Ex-Drug Company Employees Accounts for 21 at PMDA
January 17, 2011
- Top-Leaders Stress Importance of Renovation in New Year's Addresses
January 17, 2011
- Mr Hasegawa to Lead Both KEIZAI DOYUKAI, Takeda
January 17, 2011
- BI Group to Inaugurate New Business Structure in Japan
January 17, 2011
- IBL to Develop Antibody Drugs Using Transgenic Silkworm
January 17, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…